MyFinsight
Home
Blog
About
Back
Income Statement
ARVINAS, INC. (ARVN)
ARVINAS, INC. (ARVN)
source: myfinsight.com
Collaboration Agreement
Revenue-Vepdegestrant
$133,700K
License-Rigel
Pharmaceuticals Inc.
$62,500K
Milestone
Revenue-Vepdegestrant
$50,000K
Collaboration Agreement
Revenue-Pfizer Inc.
$3,500K
Revenue
$249,700K
(1014.73%↑ Y/Y)
Interest income, net
$5,500K
(-46.60%↓ Y/Y)
Income (loss) from
operations
$164,100K
(329.51%↑ Y/Y)
Total other income
$5,500K
(-45.00%↓ Y/Y)
Total operating
expenses
$85,600K
(-8.84%↓ Y/Y)
Net income (loss)
before income taxes
$169,600K
(375.77%↑ Y/Y)
Research and development
$52,600K
(-23.32%↓ Y/Y)
General and
administrative
$24,000K
(-5.14%↓ Y/Y)
Cost of license
revenue
$9,000K
Net income (loss)
$169,400K
(376.80%↑ Y/Y)
Income tax (expense)
benefit
$200K
(166.67%↑ Y/Y)
Comprehensive income (loss)
$169,000K
(373.91%↑ Y/Y)
Unrealized gain on
available-for-sale securities
-$400K
(20.00%↑ Y/Y)
Back